~~<i id='497D766865'><strike id='497D766865'><tt id='497D766865'><pre id='497D766865'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：leisure time 2025-10-01 14:40:25 - browse：8

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Stop Congress from blocking public access to science

entertainment

hotspot

entertainment

focus

Theannouncementofthesocialmediaapp'Threads'isdisplayedinApple'sUSAppStoreseenonthescreenofasmartphon

WSS

The stability of $0 premiums in Medicare Advantage

The biotech scorecard for Q4: 16 stock

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Grail is spending more than ever lobbying Congress

PhRMA sues HHS over Medicare drug price negotiation

Some top drug companies are starting to take action on climate

hotspot

Wikipedia

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Australia's humpback populations rebound raising hopes of marine scientists

As demand for Covid shots wanes, Moderna seeks its next success

European officials brace for rough respiratory virus season

As demand for Covid shots wanes, Moderna seeks its next success

2023 Nobel Prize in Medicine goes to Karikó and Weissman

In age of alternative facts, a scholarly course on calling out crap

PhRMA sues HHS over Medicare drug price negotiation

Medicare details structure of new drug price negotiation program

RSV injection headlines need to be accurate for good uptake

hotspot

These geoengineering technologies could help combat the climate crisis, scientists say

6 solutions to address cancer drug shortages and others

Meta looks to target Twitter with a rival app called Threads

Will an HIV vaccine ever be a reality?

Community addresses injustice for Long Island mothers

Australia's humpback populations rebound raising hopes of marine scientists

hotspot

hotspot

entertainment

focus